NETS
XL092-311
A phase 2/3, multicentre, randomized open-label study of zanzalintinib VS everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumours.
Trial overview
Clinical Area
Medical Oncology
Disease
NETS
Disease site
Gastrointestinal (GI)
Study Phase
II
Trial Identifiers
Registration number: NCT06943755
GenesisCare Location(s)
Principal Investigator(s)